COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB plus PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)

被引：0
|
作者：
Arreola Ornelas, H. [1 ,2 ]
Rosado Buzzo, A. [1 ]
Garcia, L. [1 ]
Camacho, L. M. [1 ]
Lechuga, D. [3 ]
机构：
[1] OikoSalud, Mexico City, DF, Mexico
[2] Fdn Mexicana Salud, Mexico City, DF, Mexico
[3] Roche Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A451 / A451
页数：1
相关论文
共 50 条
  • [1] COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB plus PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN MEXICO PUBLIC INSURANCE (SEGURO POPULAR)
    Arreola Ornelas, H.
    Rosado Buzzo, A.
    Garcia, L.
    Camacho, L. M.
    Lechuga, D.
    VALUE IN HEALTH, 2011, 14 (07) : A448 - A449
  • [2] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [3] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [4] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
  • [6] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [7] COST-EFFECTIVENESS OF PACLITAXEL MONOTHERAPY VERSUS PACLITAXEL PLUS BEVACIZUMAB COMBINATION THERAPY IN TRIPLE-NEGATIVE BREAST CANCER
    Yande, S.
    Deshmukh, A. A.
    VALUE IN HEALTH, 2022, 25 (07) : S431 - S431
  • [8] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
    Lazzaro, Carlo
    Bordonaro, Roberto
    Cognetti, Francesco
    Fabi, Alessandra
    De Placido, Sabino
    Arpino, Grazia
    Marchetti, Paolo
    Botticelli, Andrea
    Pronzato, Paolo
    Martelli, Elisa
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 125 - 135
  • [9] A FIRST COST-EFFECTIVENESS ANALYSIS BASED ON REAL LIFE CLINICAL OUTCOMES OF BEVACIZUMAB plus PACLITAXEL COMPARED TO PACLITAXEL AMONG FRENCH PATIENTS WITH HER2-METASTATIC BREAST CANCER IN FIRST LINE OF TREATMENT
    Petitjean, A.
    Roze, S.
    Tehard, B.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [10] Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 580 patients with metastatic breast cancer
    Finn, R. S.
    Press, M. F.
    Dering, J.
    Gomez, H.
    Aziz, Z.
    Arbushites, M.
    Koehler, M.
    Oliva, C.
    Williams, L. S.
    Di Leo, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 212 - 212
12345